Navigation Links
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Date:4/7/2009

will be available immediately by prescription at retail pharmacies nationwide.

In addition to RAPAFLO(TM), Watson will soon launch GELNIQUE, the first and only topical gel for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Watson also has submitted a New Drug Application for a 6-month formulation of Trelstar(R) (triptorelin pamoate), a luteinizing hormone releasing hormone (LHRH) agonist for the palliative treatment of advanced prostate cancer. Watson anticipates that FDA will take action on this application in the third quarter 2009.

About RAPAFLO

RAPAFLO(TM) is an effective, selective alpha-1 adrenergic receptor antagonist that binds with high affinity to the alpha 1a receptors concentrated in the prostate, bladder base and neck and seminal vesicles. It regulates the receptors, causing smooth muscles in these tissues to relax, resulting in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha 1B receptors that regulate smooth muscle relaxation and blood pressure effects is lower, minimizing the potential for side effects.

In two Phase 3 studies, 8 mg once-daily RAPAFLO(TM) taken for 12 weeks resulted in significant and rapid relief of BPH symptoms compared with placebo, as measured by the International Prostate Symptom Score (IPSS). IPSS includes irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying, intermittency, and weak stream) symptoms. RAPAFLO also has been proven to significantly improve Qmax scores (maximum urine flow rates) as early as two hours following first dose and at 12 weeks of treatment.

In clinical trials, RAPAFLO(TM) also demonstrated minimal electro cardiac effects on the cardiovascular system, without any meaningful prolongation of the QT interval. The most common drug-related side effect was retrograde ejaculation
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
2. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
3. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
4. Watson Launches Generic Biaxin(R) XL
5. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
6. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
7. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
8. Schering-Plough Announces Results of the Early ACS Trial
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
11. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Texas , May 28, 2015   Lexicon ... that Lexicon management will present at the Jefferies 2015 ... a.m. Eastern Time in New York ... clinical development programs and milestones. A webcast ... at www.lexpharma.com . An archived version of the ...
(Date:5/28/2015)... DEKALB, Ill. , May 28, 2015 ... Intent to explore an affiliation with Northwestern Memorial ... and NMHC will further define the affiliation, which ... "KishHealth is recognized for their commitment to ... Dean M. Harrison , President and Chief Executive ...
(Date:5/28/2015)... MONICA, Calif. , May 28, 2015 ... doctors to check a state prescription database before prescribing ... addiction and thousands of overdose deaths. SB ... Bell Gardens , will require prescribers to ... (CURES) before prescribing Schedule II and III drugs, like ...
Breaking Medicine Technology:Lexicon To Present At The Jefferies 2015 Healthcare Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:5/28/2015)... Recently, KORT Richmond, 5006 Atwood Drive, added a ... of life. The program works with those new to prosthetic ... but are still having difficulty. , According to the ... with limb loss in the United States. The main causes ... peripheral arterial disease – trauma (45%) and cancer (less than ...
(Date:5/28/2015)... Bronx, NY (PRWEB) May 28, 2015 ... Urgent Care are proud to present Dr. Alicia Almendral ... will be a big part of the newly opened ... very finest in modern cosmetic treatments. , Dr. Almendral ... experienced in the latest anti-aging and cosmetic enhancement techniques. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 On Sunday, ... Longest Day®, a team event to honor the strength, ... annually on summer solstice, the duration of this sunrise-to-sunset ... the disease and their caregivers. Participants raise funds and ... of the Alzheimer’s Association. , Teams are encouraged to ...
(Date:5/28/2015)... 28, 2015 Dr. Jenyons’ Medical ... exclusive deal to patients looking to undergo its advanced ... 30, patients will be able to get a single ... just $600. For a three-treatment package, which costs $1,800, ... no cost. , Dr. Juanita Jenyons, M.D., says Dr. ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
Breaking Medicine News(10 mins):Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... Not enough Scottish children are receiving MMR shots, say ... 92.1 per cent of two-year-olds were given the jab, which protects ... 95 per cent. , Yet, this is an ... cent. ,MMR vaccines were introduced in 1988, but ...
... medicine of Sanofi-Aventis will be made indigenously in Thailand. This ... ,As per the offer made by Sanofa-Aventis, the health ministry ... the drug. The statement released by the drug firm states ... poorer Thai patients. According to a health official the company ...
... rice bran could reduce the risk of intestinal cancer.// ... Department of Cancer Studies and Molecular Medicine, University of Leicester. ... in the laboratory has produced promising results. ... Cancer. ,The results of a controlled laboratory ...
... cancer patients unable to undergo surgery have another safe ... a new study. ,The Brown Medical ... ablation used to treat early-stage, inoperable cancer resulted in ... achieved through external beam radiation (EBT), a decades-old alternative ...
... Scientists have created the world's first human-sheep chimera - which ... ,The sheep have 15 per cent human cells ... brings the prospect of animal organs being transplanted into humans ... the University of Nevada, has spent seven years and ?5 ...
... Rift Valley Fever (RVF) among animals began on 18 ... the beginning// of February 2007 in Arusha region. A ... Country Office, WHO Regional Office for Africa, Centers for ... including active case finding and specimen collection. Two cases ...
Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:RF Ablation a Safe Alternative Option for Treating Lung Cancer 2Health News:Now Scientists Create a Sheep That's 15% Human 2Health News:Rift Valley Fever in the United Republic of Tanzania 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce large devices for vascular intervention....
Medicine Products: